Nuvectis Pharma Inc — Quarterly Cash Flow (NASDAQ:NVCT)

Financials

Total assets 18.61 M30.15 M27.01 M35.59 M31.71 M Total liabilities 8.89 M9.19 M10.13 M11.58 M13.3 M Total equity 9.71 M20.95 M16.87 M24.01 M18.41 M Total liabilities & shareholders' equities 18.61 M30.15 M27.01 M35.59 M31.71 M Total debt ————— Net debt —————

뉴스

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

누벡티스 파마, H.C. 웨인라이트 ’매수’ 등급 재확인

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

카플란, Nuvectis Pharma(NVCT) 주식 64,240달러 상당 매수

Nuvectis Pharma 회장, 28,600달러 상당의 주식 매입

Nuvectis Pharma 이사, NVCT 주식 7.5만 달러 매수

H.C. Wainwright, Nuvectis Pharma에 ’매수’ 등급 재확인, 목표가 $10

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright